ClinicalTrials.Veeva

Menu

Study on Single-cell Regulons Atlas of Pancreatic Ductal Adenocarcinoma

T

Tiejun Ying

Status

Completed

Conditions

Molecular Prognostic Model
Regulons
Pancreatic Ductal Adenocarcinoma (PDAC)

Study type

Observational

Funder types

Other

Identifiers

NCT06720454
YB M-05-01

Details and patient eligibility

About

The first purpose of this study is to reveal the gene regulatory network of pancreatic cancer by analyzing single-cell transcriptome sequencing data and to draw a pancreatic cancer regulator map. In addition, bulk transcriptome sequencing data are combined to construct and verify the genetic prognostic model of pancreatic cancer regulators, providing clinical tools for accurate prognostic stratification and personalized treatment of pancreatic cancer patients. The second purpose of this study is to explore the molecular mechanism by which the key oncogene in the gene prognostic model promotes pancreatic cancer advance. New ideas and scientific basis are provided for finding potential molecular targets for the treatment of pancreatic cancer. Thus, the investigators included a Tissue Microarray (TMA)-based cohort of 68 PDAC patient tissue samples. TMA was obtained from OUTDO BIOTECH (Shanghai, China). The study was approved by the institutional review board, and ethics document number is YB M-05-01.

Enrollment

68 patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Pancreatic ductal adenocarcinoma
  • With post-operative paraffin specimens

Exclusion criteria

  • Other types of pancreatic cancer other than pancreatic ductal adenocarcinoma
  • Without post-operative paraffin specimens or less than 20% of the paraffin sections contain cancerous tissue

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems